OncLive - Bringing the Oncology Community Together

Home

Nurses

Urology

Targeted Therapies

Interactive

Meetings

OncLive TV

Blogs

Hennessy's Highlights

Publications

Oncology Conference Multimedia

Photos From the 2011 ASH Annual Meeting and Exposition

Key Presentations and Meeting Takeaway Points From ASH

Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503

Oncology Conference Articles

Ponatinib Continues March to Potential Front-line Use in CML

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

First drug targeting Bruton’s tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Oncology Publications